| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14656566.2013.792805 |
| P698 | PubMed publication ID | 23614756 |
| P2093 | author name string | Cédric Rafat | |
| Alexandre Hertig | |||
| Isabelle Debrix | |||
| P2860 | cites work | Characteristics of plasmid-mediated quinolone resistance genes in extended-spectrum cephalosporin-resistant isolates of Klebsiella pneumoniae and Escherichia coli in Korea. | Q53477899 |
| Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. | Q53949143 | ||
| Quinolone resistance from a transferable plasmid. | Q54143628 | ||
| Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited. | Q54349458 | ||
| Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. | Q54356878 | ||
| Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study. | Q54367445 | ||
| Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin. | Q54644821 | ||
| Fluoroquinolones and risk of Achilles tendon disorders: case-control study | Q24528577 | ||
| Structure-activity and structure-side-effect relationships for the quinolone antibacterials | Q28246405 | ||
| Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis | Q28273598 | ||
| International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases | Q28304595 | ||
| Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers | Q28368062 | ||
| The changing epidemiology of Clostridium difficile infections | Q28750385 | ||
| Safety of trovafloxacin in treatment of lower respiratory tract infections | Q29302041 | ||
| Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network | Q30671029 | ||
| Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings | Q33151312 | ||
| Peripheral neuropathy associated with fluoroquinolones. | Q33956873 | ||
| Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers | Q33979750 | ||
| Mechanisms of action and resistance of older and newer fluoroquinolones | Q34030757 | ||
| Safety profile of the fluoroquinolones: focus on levofloxacin | Q34110521 | ||
| An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project | Q34166158 | ||
| Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose | Q34230275 | ||
| Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections | Q34233075 | ||
| The worldwide emergence of plasmid-mediated quinolone resistance | Q34569740 | ||
| Safety considerations of fluoroquinolones in the elderly: an update | Q34617485 | ||
| QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications | Q34634216 | ||
| Population-based epidemiologic analysis of acute pyelonephritis | Q34643113 | ||
| Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence | Q34722890 | ||
| Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections | Q34755148 | ||
| Clinical role of protein binding of quinolones | Q34774058 | ||
| Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy | Q34782587 | ||
| Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study | Q35065834 | ||
| Adverse drug reactions: implications for the development of fluoroquinolones | Q35110233 | ||
| Molecular characterization and antimicrobial susceptibility testing of Escherichia coli isolates from patients with urinary tract infections in 20 Chinese hospitals | Q35140054 | ||
| In vitro activity of DR-3355, an optically active ofloxacin | Q35563775 | ||
| Tissue penetration of ciprofloxacin after single and multiple doses | Q35649002 | ||
| Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates | Q35758933 | ||
| Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients | Q35814807 | ||
| In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010 | Q35867468 | ||
| Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity | Q35874779 | ||
| Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community | Q36139832 | ||
| Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy. | Q36309226 | ||
| Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study | Q36315127 | ||
| Global fluoroquinolone resistance epidemiology and implictions for clinical use. | Q36337074 | ||
| Antimicrobial drug use and resistance in Europe | Q37072235 | ||
| Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr. | Q37121180 | ||
| Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis | Q37333147 | ||
| Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid | Q37333151 | ||
| Seizures associated with levofloxacin: case presentation and literature review | Q37586997 | ||
| High rates of quinolone resistance among urinary tract infections in the ED. | Q37809379 | ||
| Quinolones: review of psychiatric and neurological adverse reactions | Q37876399 | ||
| Levofloxacin and sparfloxacin: new quinolone antibiotics | Q37881273 | ||
| The clinical pharmacokinetics of levofloxacin | Q37883517 | ||
| The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens | Q37952621 | ||
| Urinary tract infections: from pathogenesis to treatment | Q38601248 | ||
| Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy | Q39475894 | ||
| Target site concentrations of ciprofloxacin after single intravenous and oral doses | Q39671107 | ||
| Dose ranging study and constant infusion evaluation of ciprofloxacin | Q39851558 | ||
| Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1. | Q39913975 | ||
| Relentless increase of resistance to fluoroquinolones and expanded-spectrum cephalosporins in Escherichia coli: 20 years of surveillance in resource-limited settings from Latin America. | Q40026083 | ||
| Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers | Q40085961 | ||
| Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli | Q41788804 | ||
| Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis | Q42000458 | ||
| Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010 | Q42326525 | ||
| Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials | Q42671287 | ||
| Acute hepatitis associated with the use of levofloxacin | Q42769295 | ||
| A multilevel analysis of trimethoprim and ciprofloxacin prescribing and resistance of uropathogenic Escherichia coli in general practice | Q43067192 | ||
| Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis | Q43131129 | ||
| Post-antibiotic effect of levofloxacin and tobramycin alone or in combination with cefepime against Pseudomonas aeruginosa | Q43227185 | ||
| Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). | Q43260620 | ||
| Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis | Q43490572 | ||
| Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose | Q43552321 | ||
| A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection | Q43588339 | ||
| Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin | Q43838827 | ||
| Diagnosis and treatment of acute uncomplicated urethritis of men: guidelines from the French committee of infectious disease of the French association of urology (CIAFU) | Q43984309 | ||
| Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 114 clinical isolates of Pseudomonas aeruginosa derived from urinary tract infections and their rapid detection by denaturing high-performance liquid chromatography | Q44176682 | ||
| Investigation of extended-spectrum beta-lactamase in Klebsiellae pneumoniae and Escherichia coli from China | Q44233614 | ||
| Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000). | Q44256805 | ||
| Does in vitro fluoroquinolone resistance predict clinical failure in urinary tract infections? | Q44259675 | ||
| Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States | Q44319820 | ||
| Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Prog | Q44429062 | ||
| Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). | Q44682711 | ||
| Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. | Q44702078 | ||
| Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. | Q45024851 | ||
| Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. | Q45044150 | ||
| National trends in emergency department antibiotic prescribing for elders with urinary tract infection, 1996-2005. | Q45392125 | ||
| Severe dysglycemia with the fluoroquinolones: a class effect? | Q45958852 | ||
| The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. | Q45977952 | ||
| Temporal changes in the prevalence of community-acquired antimicrobial-resistant urinary tract infection affected by Escherichia coli clonal group composition | Q46157735 | ||
| Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates | Q46341336 | ||
| Coadministration of oral levofloxacin with agents that impair absorption: impact on antibiotic resistance | Q46353499 | ||
| A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. | Q46408982 | ||
| Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli | Q46420220 | ||
| Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). | Q46768925 | ||
| A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis | Q46777303 | ||
| Is plasmid-mediated quinolone resistance a clinically significant problem? | Q46812075 | ||
| Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis | Q46835528 | ||
| Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase | Q46862305 | ||
| Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). | Q47431912 | ||
| In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004). | Q50072973 | ||
| In-vitro activity of DR-3355, an optically active isomer of ofloxacin, against bacterial pathogens associated with travellers' diarrhoea | Q50193568 | ||
| Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). | Q50940090 | ||
| Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada--results of the CANWARD 2007-2009 study. | Q51499617 | ||
| A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. | Q51736675 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | levofloxacin | Q424193 |
| P304 | page(s) | 1241-1253 | |
| P577 | publication date | 2013-04-24 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Levofloxacin for the treatment of pyelonephritis | |
| P478 | volume | 14 |
| Q41268262 | Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). |
| Q39905753 | Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial |
| Q38416227 | For Single Dosing, Levofloxacin Is Superior to Ciprofloxacin When Combined With an Aminoglycoside in Preventing Severe Infections After Prostate Biopsy |
| Q36204123 | Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections |
Search more.